Evidence map›Paper›PMID 34439148›Full record

ArticleCancers2021

Preliminary Report on Computed Tomography Radiomics Features as Biomarkers to Immunotherapy Selection in Lung Adenocarcinoma Patients.

Vincenza Granata, Roberta Fusco, Matilde Costa, Carmine Picone, Diletta Cozzi, Chiara Moroni, Giorgia Viola La Casella, Agnese Montanino, Riccardo Monti, Francesca Mazzoni and 6 more

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Exploring Radiologists' Burnout in the COVID-19 Era: A Narrative Review.International journal of environmental research and public health · 2023
    Review
  17. Review
  18. Review
  19. Review
  20. Gender Medicine in Clinical Radiology Practice.Journal of personalized medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Vincenza GranataDivision of Radiology, Istituto Nazionale Tumori IRCCS Fondazione Pascale-IRCCS di Napoli, I-80131 Naples, Italy.
Roberta FuscoMedical Oncology Division, Igea SpA, I-80013 Naples, Italy.
Matilde CostaR & D Lab. of Tecnologie Avanzate TA Srl, Science and Technology Park, I-10153 Udine, Italy.
Carmine PiconeDivision of Radiology, Istituto Nazionale Tumori IRCCS Fondazione Pascale-IRCCS di Napoli, I-80131 Naples, Italy.
Diletta CozziDivision of Radiodiagnostic, Azienda Ospedaliero-Universitaria Careggi, I-50134 Firenze, Italy.ORCID 0000-0001-7028-9047
Chiara MoroniDivision of Radiodiagnostic, Azienda Ospedaliero-Universitaria Careggi, I-50134 Firenze, Italy.
Giorgia Viola La CasellaDivision of Radiodiagnostic, Università degli Studi della Campania Luigi Vanvitelli, I-80128 Naples, Italy.
Agnese MontaninoThoracic Medical Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale-IRCCS di Napoli, I-80131 Naples, Italy.
Riccardo MontiDivision of Radiodiagnostic, Università degli Studi della Campania Luigi Vanvitelli, I-80128 Naples, Italy.
Francesca MazzoniDivision of Oncology, Azienda Ospedaliero-Universitaria Careggi, I-50134 Firenze, Italy.
Roberta GrassiItalian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, I-20122 Milan, Italy.
Valeria Grazia MalagninoDipartimento Diagnosi e Terapia per Immagini, Radiologia Diagnostica, IRCCS Istituto Tumori G, Paolo II, I-70124 Bari, Italy.
Salvatore CappabiancaDivision of Radiodiagnostic, Università degli Studi della Campania Luigi Vanvitelli, I-80128 Naples, Italy.
Roberto GrassiItalian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, I-20122 Milan, Italy.
Vittorio MieleDivision of Radiodiagnostic, Azienda Ospedaliero-Universitaria Careggi, I-50134 Firenze, Italy.ORCID 0000-0002-7848-1567
Antonella PetrilloDivision of Radiology, Istituto Nazionale Tumori IRCCS Fondazione Pascale-IRCCS di Napoli, I-80131 Naples, Italy.ORCID 0000-0003-2465-5370

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the efficacy of radiomics features obtained by computed tomography (CT) examination as biomarkers in order to select patients with lung adenocarcinoma who would benefit from immunotherapy.

methodsSeventy-four patients (median age 63 years, range 42-86 years) with histologically confirmed lung cancer who underwent immunotherapy as first- or second-line therapy and who had baseline CT studies were enrolled in this approved retrospective study. As a control group, we selected 50 patients (median age 66 years, range 36-86 years) from 2005 to 2013 with histologically confirmed lung adenocarcinoma who underwent chemotherapy alone or in combination with targeted therapy. A total of 573 radiomic metrics were extracted: 14 features based on Hounsfield unit values specific for lung CT images; 66 first-order profile features based on intensity values; 43 second-order profile features based on lesion shape; 393 third-order profile features; and 57 features with higher-order profiles. Univariate and multivariate statistical analysis with pattern recognition approaches and the least absolute shrinkage and selection operator (LASSO) method were used to assess the capability of extracted radiomics features to predict overall survival (OS) and progression free survival (PFS) time.

resultsA total of 38 patients (median age 61; range 41-78 years) with confirmed lung adenocarcinoma and subjected to immunotherapy satisfied inclusion criteria, and 50 patients in a control group were included in the analysis The shift in the center of mass of the lesion due to image intensity was significant both to predict OS in patients subjected to immunotherapy and to predict PFS in patients subjected to immunotherapy and in patients in the control group. With univariate analysis, low diagnostic accuracy was reached to stratify patients based on OS and PFS time. Regarding multivariate analysis, considering the robust (two morphological features, three textural features and three higher-order statistical metrics) application of the LASSO approach and all patients, a support vector machine reached the best results for stratifying patients based on OS (area under curve (AUC) of 0.89 and accuracy of 81.6%). Alternatively, considering the robust predictors (six textural features and one higher-order statistical metric) and application of the LASSO approach including all patients, a decision tree reached the best results for stratifying patients based on PFS time (AUC of 0.96 and accuracy of 94.7%).

conclusionsSpecific radiomic features could be used to select patients with lung adenocarcinoma who would benefit from immunotherapy because a subset of imaging radiomic features useful to predict OS or PFS time were different between the control group and the immunotherapy group.

Indexed as

computed tomographylung adenocarcinomamorphological analysisradiomicstexture analysis

Identifiers

PMID34439148
PMCPMC8393664

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.